NEWARK, Calif. — CymaBay Therapeutics, Inc., a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational treatment, seladelpar, for the management of primary biliary cholangitis,...
research News
The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices. In individuals carrying mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes an ion channel controlling the...
BETHESDA, Md. — The Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis. Prime Medicine is using a gene editing technology called prime editing — a technology that enables insertions or deletions of small segments of...
VANCOUVER, Wash. — CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA. The Company believes this submission will lead to the removal of the...
Sydney, Australia – In good news for office workers, a new study from the University of Sydney’s Charles Perkins Centre has found increasing your step count may counteract the health consequences of too much sedentary time each day. The study of over 72,000 people, published in the British Journal of...
Boston, Mass. – Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in...
SAN FRANCISCO, Calif. — Today marks a turning point in the battle against Alzheimer’s disease as Darmiyan, Inc., a leading company in brain health innovation announces the FDA’s approval of its first-in-class (De Novo) clinical test, BrainSee. This approval marks a pivotal advancement in brain health and opens the door to...
Hanover, New Hampshire – Findings from a new study conducted by a team of researchers at Dartmouth’s Geisel School of Medicine and Thayer School of Engineering and published in Cell Reports Medicine, offer new insights into how antibodies function in combating herpes simplex virus (HSV) infections. Their research may lead to possible...
Hanover, New Hampshire – Findings from a new study conducted by a team of researchers at Dartmouth’s Geisel School of Medicine and published in the journal mBio, reflect the important role that the gut microbiome (communities of bacteria) plays in the airway health of persons with cystic fibrosis. Cystic fibrosis is an inherited...
Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association...